June 2014

When it comes to the personalized treatment of genitourinary cancers, biomarkers hold an immense amount of promise. Already, there are predictive and prognostic tools available to urologists.

Research from Chile suggests that low levels of free testosterone indicate that an apparently low-risk case of prostate cancer will require treatment.

The American Urological Association (AUA) has added recommendations for the use of radium-223 to its treatment guidelines for castration-resistant prostate cancer

I am sure that those of you who attended the AUA meeting in Orlando were struck by the number of presentations on the use of biomarkers and their role in better risk stratification and management of the urologic oncology patient.

When a patient develops advanced prostate cancer, that doesn't mean his urologist needs to bid him farewell.

Two recently approved drugs for the treatment of advanced prostate cancer-radium-223 (Xofigo) and abiraterone acetate (Zytiga)-will be studied in combination in a phase III clinical trial.

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists in collaboration with oncologists and primary-care physicians.

The world's largest gathering of urologists, the annual meeting of the American Urological Association, offered an array of information relevant to those who practice in the community setting.